The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men

Clinical Science

Volumn 113, Issue 11-12, 2007, Pages 435-441

  Scartezini, Marileia ^a,b   Hubbart, Christina ^b   Whittall, Ros A ^b   Cooper, Jackie A ^b   Neil, Andrew H W ^c   Humphries, Steve E ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apolipoprotein B (ApoB); Cardiovascular risk; Coronary heart disease; Familial hypercholesterolaemia; Low density lipoprotein cholesterol (LDL C); Protein convertase subtilisin kexin type 9 gene (PCSK9); Total cholesterol

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PCSK9 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 36849085368     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070150     Document Type: Article

References (26)

1. Horton, J. D., Cohen, J. C. and Hobbs, H. H. (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71-77
2. Maxwell, K. N., Fisher, E. A. and Breslow, J. L. (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. U.S.A. 102, 2069-2074
3. Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A., Berge, K. E. and Leren, T. P. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15, 1551-1558
4. Abifadel, M., Varret, M., Rabes, J. P. et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156
5. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A. et al. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523
6. Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K. and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165
7. Cohen, J. C., Boerwinkle, E., Mosley, Jr, T. H. and Hobbs, H. H. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272
8. Kotowski, I. K., Pertsemlidis, A., Luke, A. et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410-422
9. Shioji, K., Mannami, T., Kokubo, Y. et al. (2004) Genetic variants in PCSK9 affect the cholesterol level in Japanese. J. Hum. Genet. 49, 109-114
10. Chen, S. N., Ballantyne, C. M., Gotto, Jr, A. M., Tan, Y., Willerson, J. T. and Marian, A. J. (2005) A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol. 45, 1611-1619
11. Berge, K. E., Ose, L. and Leren, T. P. (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26, 1094-1100
12. Miller, G. J., Bauer, K. A., Barzegar, S. et al. (1995) The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb. Haemostasis 73, 82-86
13. Miller, G. J., Bauer, K. A., Barzegar, S., Cooper, J. A. and Rosenberg, R. D. (1996) Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb. Haemostasis 75, 767-771
14. Neil, H. A., Seagroatt, V., Betteridge, D. J. et al. (2004) Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 90, 1431-1437
15. Prineas, R. J., Crow, R. S. and Blackburn, H. (1982) The Minnesota Code Manual of Electrocardiographic Findings: standards and procedures for measurement and classification. Boston, USA, John Wright PSC
16. Medical Research Council (1995) Committee on Chronic Bronchitis and Questionaire on Respiratory Symptoms, Medical Research Council Publications Group, London
17. World Health Organization (1976) Myocardial Infarction Community Registers: Results of a WHO International Collaborative Study Coordinated by the Regional Office for Europe, World Health Organization, Copenhagen
18. Scientific Steering Committee on behalf of The Simon Broome Register Group (1991) The risk of fatal coronary heart disease in familial hypercholesterolaemia. Br. Med. J. 303, 893-896
19. Humphries, S. E., Whittall, R. A., Hubbart, C. S. et al. (2006) Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43, 943-949
20. Heath, K. E., Humphries, S. E., Middleton-Price, H. and Boxer, M. (2001) A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur. J. Hum. Genet. 9, 244-252
21. Day, I. N. and Humphries, S. E. (1994) Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal. Biochem. 222, 389-395
22. Baigent, C., Keech, A., Kearney, P. M. et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278
23. Slack, J. (1969) Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet ii, 1380-1382
24. Kotze, M. J., De Villiers, W. J., Steyn, K. et al. (1993) Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler. Thromb. 13, 1460-1468
25. Davignon, J., Cohn, J. S., Mabile, L. and Bernier, L. (1999) Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin. Chim. Acta 286, 115-143
26. Webb, J. C., Patel, D. D., Shoulders, C. C., Knight, B. L. and Soutar, A. K. (1996) Genetic variation at a splicing branch point in intron 9 of the low density lipoprotein (LDL)-receptor gene: a rare mutation that disrupts mRNA splicing in a patient with familial hypercholesterolaemia and a common polymorphism. Hum. Mol. Genet. 5, 1325-1331